Cabaletta's Burn Rate Soars Amid R&D Push, Raising Going Concern Doubts

Ticker: CABA · Form: 10-Q · Filed: Nov 10, 2025 · CIK: 1759138

Sentiment: bearish

Topics: Biotechnology, Clinical Stage, Going Concern, Cash Burn, R&D Expenses, Autoimmune Disease, Dilution

TL;DR

**Cabaletta is burning cash at an alarming rate and needs a major capital injection by mid-2026 or its promising pipeline is toast.**

AI Summary

Cabaletta Bio, Inc. (CABA) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $125.9 million, up from $83.3 million in the same period of 2024. This 51.1% increase was primarily driven by a substantial rise in research and development (R&D) expenses, which climbed to $106.5 million from $71.7 million, reflecting intensified clinical trial activities for rese-cel and MuSK-CAART. The company's cash and cash equivalents decreased sharply to $60.2 million as of September 30, 2025, from $164.0 million at December 31, 2024, indicating a high burn rate. Despite raising $93.6 million from the issuance of common stock, warrants, and pre-funded warrants, and an additional $2.6 million from an ATM offering, the company explicitly stated conditions that raise substantial doubt about its ability to continue as a going concern, projecting current funding to last only into the second half of 2026. Strategic outlook remains focused on advancing its RESET™ and MusCAARTes™ clinical trials, but significant additional funding is required to complete development and achieve commercialization. The company faces risks related to manufacturing dependencies on partners like University of Pennsylvania, Minaris, and Lonza, and the need to secure further intellectual property protection.

Why It Matters

Cabaletta Bio's escalating net loss and dwindling cash reserves are critical for investors, signaling a high-risk profile for this clinical-stage biotech. The explicit 'going concern' warning means CABA must secure substantial additional funding by mid-2026, or face potential delays or discontinuation of its promising rese-cel and MuSK-CAART programs. This financial pressure could force dilutive equity raises, impacting existing shareholders. For employees and customers, the company's ability to continue operations directly affects job security and the future availability of potential therapies. In the competitive autoimmune disease market, CABA's financial instability could hinder its ability to compete with better-capitalized rivals, potentially delaying or preventing the commercialization of its innovative B cell ablation platform.

Risk Assessment

Risk Level: high — The company explicitly states, "We have identified conditions that raise substantial doubt about our ability to continue as a going concern." This is directly supported by a net loss of $125.9 million for the nine months ended September 30, 2025, and a significant decrease in cash and cash equivalents from $163.9 million at December 31, 2024, to $60.2 million at September 30, 2025, indicating a rapid cash burn.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Given the explicit going concern warning and high cash burn, potential investors should await clear evidence of successful, non-dilutive financing or significant positive clinical milestones before considering a position. Existing investors should evaluate their risk tolerance and the potential for further dilution.

Financial Highlights

debt To Equity
N/A
revenue
N/A
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$125.9M
eps
N/A
gross Margin
N/A
cash Position
$60.2M
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is Cabaletta Bio's current financial runway?

Cabaletta Bio's current cash position is projected to enable its operations only into the second half of 2026, as stated in the 10-Q, raising substantial doubt about its ability to continue as a going concern without additional funding.

How much did Cabaletta Bio spend on R&D in the last nine months?

For the nine months ended September 30, 2025, Cabaletta Bio's research and development expenses totaled $106.48 million, a significant increase from $71.67 million in the same period of 2024.

What are the primary risks for Cabaletta Bio investors?

Key risks include the explicit 'going concern' warning, high dependence on third-party manufacturers like Penn, Minaris, and Lonza, the need for substantial additional funding, and the inherent uncertainties of clinical trial success and regulatory approval for product candidates like rese-cel and MuSK-CAART.

Has Cabaletta Bio raised capital recently?

Yes, Cabaletta Bio raised $93.56 million from the issuance of common stock, warrants, and pre-funded warrants, and an additional $2.60 million from an 'at-the-market' (ATM) offering during the nine months ended September 30, 2025.

What are Cabaletta Bio's main product candidates?

Cabaletta Bio's main product candidates are resecabtagene autoleucel (rese-cel, formerly CABA-201) for its Phase 1/2 RESET™ clinical trials and MuSK-CAART for its Phase 1 MusCAARTes™ trial.

How has Cabaletta Bio's cash position changed?

Cabaletta Bio's cash and cash equivalents decreased significantly from $163.96 million at December 31, 2024, to $60.21 million at September 30, 2025, reflecting a net decrease of $103.76 million.

What is the impact of increased R&D expenses on Cabaletta Bio?

The increased R&D expenses, up to $106.48 million, indicate accelerated development of their product candidates but also contribute significantly to the company's growing net loss of $125.94 million and rapid cash burn, necessitating further financing.

What is the significance of the 'going concern' disclosure for Cabaletta Bio?

The 'going concern' disclosure means that Cabaletta Bio's auditors believe there is substantial doubt about the company's ability to continue operating for at least one year without securing additional funding, signaling high financial instability and risk for investors.

What are Cabaletta Bio's intellectual property dependencies?

Cabaletta Bio is reliant on intellectual property licensed from the University of Pennsylvania (Penn) and Nanjing IASO Biotherapeutics Co., Ltd. (IASO), with termination of these agreements posing a material adverse effect on its business.

What is Cabaletta Bio's strategy to address its funding needs?

Cabaletta Bio's strategy involves raising substantial additional funding through various offerings, such as 'at-the-market' offerings and other equity issuances, to extend its cash runway beyond the second half of 2026 and support its product development programs.

Risk Factors

Industry Context

Cabaletta Bio operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel cell therapies for autoimmune diseases. The industry is characterized by long development cycles, high R&D costs, significant regulatory hurdles, and the need for substantial funding to advance candidates through clinical trials and towards commercialization. Success often hinges on demonstrating clinical efficacy and safety, securing intellectual property, and managing complex manufacturing processes.

Regulatory Implications

The company faces significant regulatory scrutiny inherent in developing novel cell therapies. Ensuring compliance with FDA and other global regulatory bodies throughout clinical development and manufacturing is critical. Delays or setbacks in regulatory approvals for its lead candidates, rese-cel and MuSK-CAART, could severely impact its financial condition and future prospects.

What Investors Should Do

  1. Monitor cash runway closely.
  2. Evaluate R&D progress and clinical trial data.
  3. Assess manufacturing partnership stability.
  4. Consider the impact of ongoing dilution.

Key Dates

Glossary

rese-cel
A specific cell therapy candidate developed by Cabaletta Bio. (Intensified clinical trial activities for rese-cel are a primary driver of increased R&D expenses.)
MuSK-CAART
A specific cell therapy candidate developed by Cabaletta Bio targeting MuSK-positive generalized myasthenia gravis. (Intensified clinical trial activities for MuSK-CAART are a primary driver of increased R&D expenses.)
ATM offering
At-the-market offering, a method for companies to sell stock over time at prevailing market prices. (The company raised an additional $2.6 million through an ATM offering, contributing to its cash position but also indicating ongoing capital needs.)
Going concern
An accounting assumption that a business will continue to operate for the foreseeable future. (The company explicitly states conditions that raise substantial doubt about its ability to continue as a going concern, highlighting significant financial risks.)
Accumulated deficit
The total cumulative net losses of a company since its inception, less any cumulative net income. (The accumulated deficit increased to $475.0M, reflecting the company's history of operating losses.)

Year-Over-Year Comparison

Compared to the prior year period, Cabaletta Bio has experienced a substantial increase in its net loss, rising by 51.1% to $125.9 million for the nine months ended September 30, 2025, primarily driven by a 48.5% surge in R&D expenses to $106.5 million. This heightened investment in clinical trials has led to a significant depletion of cash reserves, with cash and cash equivalents falling to $60.2 million from $164.0 million at the end of 2024. While the company raised capital through stock issuances, it faces heightened going concern risks and increased operational dependencies.

Filing Stats: 4,376 words · 18 min read · ~15 pages · Grade level 20 · Accepted 2025-11-10 07:37:04

Key Financial Figures

Filing Documents

Financial Statements (Unaudited)

Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Operations and Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 8 Notes to Unaudited Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 39 PART II. OTHER INFORMATION 40 Item 1.

Legal Proceedings

Legal Proceedings 40 Item 1A.

Risk Factors

Risk Factors 40 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 101 Item 3. Defaults Upon Senior Securities 101 Item 4. Mine Safety Disclosures 101 Item 5. Other Information 101 Item 6. Exhibits 102

Signatures

Signatures 103 i Summary of the Material and Other Risks Associated with Our Business We are a clinical-stage company with a limited operating history, have incurred significant losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We are highly dependent on our relationships with University of Pennsylvania, or Penn, Minaris Advanced Therapies, LLC, or Minaris (f/k/a WuXi Advanced Therapies, Inc) and/or Lonza Houston Inc., or Lonza, for our current manufacturing needs for our Phase 1/2 RESET TM , or Restoring Self-Tolerance, clinical trials for resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and our Phase 1 clinical trial of MuSK-CAART, or the MusCAARTes TM trial, and if manufacturing capacity at any of these manufacturing partners is reduced or otherwise delayed or limited, including due to legislative action, or if we, Penn, Minaris, Lonza or any third-party manufacturers encounter difficulties in manufacturing our product candidates, this could adversely impact the supply of product candidates for and enrollment in our trials. We are reliant on intellectual property licensed to us by Penn and Nanjing IASO Biotherapeutics Co., Ltd., or IASO, and termination of one of these license agreements would result in the loss of significant rights, which would have a material adverse effect on our business. If we are unable to obtain and maintain sufficient intellectual property protection for our current product candidates and technologies or any future product candidates, we may not be able to compete effectively in our markets. We will need to raise substantial additional funding before we can expect to complete development of any of our product candidates or generate any revenues from product sales. Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. If we are unable to su

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements. CABALETTA BIO, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) September 30, 2025 December 31, 2024 Assets (unaudited) Current assets: Cash and cash equivalents $ 60,206 $ 163,962 Short-term investments 99,725 — Prepaid expenses and other current assets 4,630 2,713 Total current assets 164,561 166,675 Property and equipment, net 2,063 2,743 Finance lease right-of-use assets 15,931 7,020 Operating lease right-of-use assets 3,597 6,315 Other assets 3,607 2,293 Total assets $ 189,759 $ 185,046 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 8,267 $ 4,923 Accrued and other current liabilities 16,246 12,188 Finance lease liabilities, current portion 17,596 5,989 Operating lease liabilities, current portion 3,626 3,986 Total current liabilities 45,735 27,086 Finance lease liabilities, net of current portion 4,558 3,241 Operating lease liabilities, net of current portion — 2,384 Total liabilities 50,293 32,711 Commitments and contingencies (see Notes 5 and 6) Stockholders' equity: Preferred stock, $ 0.00001 par value: 10,000,000 shares authorized as of September 30, 2025 and December 31, 2024; no shares issued or outstanding at September 30, 2025 and December 31, 2024 — — Voting and non-voting common stock, $ 0.00001 par value: 300,000,000 ( 293,590,481 voting and 6,409,519 non-voting) shares authorized as of September 30, 2025 and 150,000,000 ( 143,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2024; 96,265,204 voting shares issued and outstanding as of September 30, 2025 and 50,743,101 voting shares issued and outstanding as of December 31, 2024 1 1 Additional paid-in capital 614,480 501,435 Accumulated other comprehensive income 23 — Accumulated deficit ( 475,038 )

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing